• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆纤维蛋白原、D - 二聚体和血管性血友病因子作为慢性血液透析患者心血管疾病发病率标志物的有效性

Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis.

作者信息

Kirmizis Dimitrios, Tsiandoulas Apostolos, Pangalou Maria, Koutoupa Evangelia, Rozi Paraskevi, Protopappa Maria, Barboutis Konstantinos

机构信息

Department of Nephrology, Serres General Hospital, Serres, Greece.

出版信息

Med Sci Monit. 2006 Feb;12(2):CR55-62. Epub 2006 Jan 26.

PMID:16449948
Abstract

BACKGROUND

Among the non-classic cardiovascular disease risk factors in end-stage renal disease patients on chronic hemodialysis (HD), plasma fibrinogen, D-dimer, and von Willebrand factor (vWf) levels are potential markers of cardiovascular morbidity. We designed this case-control study to investigate their validity and any differences between them.

MATERIAL/METHODS: Twenty-five HD patients (18 males, mean age: 63, range: 52-69 years) comprised the group with prevalent cardiovascular disease (CVD) and 50 HD patients (35 males, mean age: 62, range: 40-77 years) with non-evident cardiovascular disease history constituted the second study group. Twenty-five healthy non-smoking volunteers served as controls for comparison with the study groups.

RESULTS

Patients with CVD had significantly higher concentrations of plasma fibrinogen, D-dimer, and vWf than patients without incident CVD. All three parameters correlated positively with cardiovascular morbidity, i.e. fibrinogen (r=0.378, P<0.001), logDD (r=0.70, P<0.001), vWf (r=0.214, P<0.001), and logCRP (r=0.704, P<0.001). Among them, D-dimer exhibited the characteristics most coherent with CVD. The age- and sex-adjusted odds ratio (OR) of D-dimer for the presence of CVD was 2.0, which did not change appreciably when adjustments for several pathophysiological clusters of variables were made, except for a marginal reduction in OR following adjustment for markers of inflammation.

CONCLUSIONS

Among the coagulation molecules studied, plasma D-dimer levels exhibited the characteristics most coherent with associated CVD and were found to be strongly and independently associated with the prevalence of CVD in HD patients.

摘要

背景

在接受慢性血液透析(HD)的终末期肾病患者的非经典心血管疾病危险因素中,血浆纤维蛋白原、D - 二聚体和血管性血友病因子(vWf)水平是心血管疾病发病的潜在标志物。我们设计了这项病例对照研究来调查它们的有效性以及它们之间的差异。

材料/方法:25名HD患者(18名男性,平均年龄:63岁,范围:52 - 69岁)组成患有心血管疾病(CVD)的组,50名无明显心血管疾病史的HD患者(35名男性,平均年龄:62岁,范围:40 - 77岁)构成第二个研究组。25名健康非吸烟志愿者作为对照组与研究组进行比较。

结果

患有CVD的患者血浆纤维蛋白原、D - 二聚体和vWf的浓度显著高于无CVD的患者。所有这三个参数与心血管疾病发病率呈正相关,即纤维蛋白原(r = 0.378,P < 0.001)、logDD(r = 0.70,P < 0.001)、vWf(r = 0.214,P < 0.001)和logCRP(r = 0.704,P < 0.001)。其中,D - 二聚体表现出与CVD最相关的特征。D - 二聚体在存在CVD时经年龄和性别调整的优势比(OR)为2.0,在对几个病理生理变量组进行调整时,该值没有明显变化,除了在对炎症标志物进行调整后OR略有降低。

结论

在所研究的凝血分子中,血浆D - 二聚体水平表现出与相关CVD最相关的特征,并且发现其与HD患者CVD的患病率密切且独立相关。

相似文献

1
Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis.血浆纤维蛋白原、D - 二聚体和血管性血友病因子作为慢性血液透析患者心血管疾病发病率标志物的有效性
Med Sci Monit. 2006 Feb;12(2):CR55-62. Epub 2006 Jan 26.
2
Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.原发性甲状旁腺功能亢进患者的血液凝固、纤维蛋白溶解和血脂谱:血浆因子VII和X活性及D-二聚体水平升高。
Exp Clin Endocrinol Diabetes. 2008 Nov;116(10):619-24. doi: 10.1055/s-2008-1065365. Epub 2008 May 16.
3
Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients.血浆总唾液酸水平升高是肾透析患者心血管疾病的标志物。
J Nephrol. 2003 Jul-Aug;16(4):540-5.
4
Patient characteristics rather than the type of dialyser predict the variability of endothelial derived surface molecules in chronic haemodialysis patients.在慢性血液透析患者中,是患者特征而非透析器类型预测内皮衍生表面分子的变异性。
Nephrol Dial Transplant. 2005 Dec;20(12):2751-8. doi: 10.1093/ndt/gfi126. Epub 2005 Sep 27.
5
Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.止血因子与冠状动脉疾病患者心血管死亡风险:动脉粥样基因研究
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2793-9. doi: 10.1161/01.ATV.0000249406.92992.0d. Epub 2006 Oct 5.
6
Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease.患有和未患有缺血性心脏病的透析患者的凝血和纤维蛋白溶解因子
Adv Perit Dial. 2000;16:152-5.
7
Cardiovascular risk factors in non-diabetic hemodialysis patients: a comparative study.非糖尿病血液透析患者的心血管危险因素:一项对比研究。
Ren Fail. 2009;31(2):91-7. doi: 10.1080/08860220802595484.
8
Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease.终末期肾病患者血清瘦素、脂联素和抵抗素浓度及其与心血管疾病的关系。
Clin Endocrinol (Oxf). 2005 Feb;62(2):242-9. doi: 10.1111/j.1365-2265.2005.02207.x.
9
Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.矿物质代谢与心血管疾病发病率及死亡风险:腹膜透析患者与血液透析患者的比较
Nephrol Dial Transplant. 2006 Sep;21(9):2513-20. doi: 10.1093/ndt/gfl257. Epub 2006 Jun 24.
10
Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation.强直性脊柱炎男性患者与非炎症性对照受试者的心血管风险参数:全身炎症的相关性
Clin Sci (Lond). 2005 Aug;109(2):171-6. doi: 10.1042/CS20040326.

引用本文的文献

1
The Joint Effect of Renal Function Status and Coagulation Biomarkers on In-Hospital Outcomes in Acute Ischemic Stroke Patients With Intravenous Thrombolysis.肾功能状态与凝血生物标志物对急性缺血性卒中静脉溶栓患者院内结局的联合影响
Immun Inflamm Dis. 2024 Dec;12(12):e70099. doi: 10.1002/iid3.70099.
2
The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients.终末期肾病患者血栓炎症生物标志物的相关性及其与循环糖胺聚糖的关系。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231169512. doi: 10.1177/10760296231169512.
3
NETs-Induced Thrombosis Impacts on Cardiovascular and Chronic Kidney Disease.
NETs 诱导的血栓形成对心血管和慢性肾脏病的影响。
Circ Res. 2023 Apr 14;132(8):933-949. doi: 10.1161/CIRCRESAHA.123.321750. Epub 2023 Apr 13.
4
Terminal Phase Components of the Clotting Cascade in Patients with End-Stage Renal Disease Undergoing Hemodiafiltration or Hemodialysis Treatment.终末期肾病行血液透析滤过或血液透析患者凝血级联的终末相成分。
Int J Mol Sci. 2020 Nov 10;21(22):8426. doi: 10.3390/ijms21228426.
5
Blood coagulation system in patients with chronic kidney disease: a prospective observational study.慢性肾脏病患者的血液凝固系统:一项前瞻性观察研究。
BMJ Open. 2017 Jun 1;7(5):e014294. doi: 10.1136/bmjopen-2016-014294.
6
Influence of ACE I/D Polymorphism on Circulating Levels of Plasminogen Activator Inhibitor 1, D-Dimer, Ultrasensitive C-Reactive Protein and Transforming Growth Factor β1 in Patients Undergoing Hemodialysis.ACE I/D多态性对血液透析患者血浆纤溶酶原激活物抑制剂1、D-二聚体、超敏C反应蛋白及转化生长因子β1水平的影响
PLoS One. 2016 Mar 29;11(3):e0150613. doi: 10.1371/journal.pone.0150613. eCollection 2016.
7
Correlation of Inflammation and Lipoprotein (a) with Hypercoagulability in Hemodialysis Patients.血液透析患者炎症及脂蛋白(a)与高凝状态的相关性
Med Arch. 2015 Aug;69(4):232-5. doi: 10.5455/medarh.2015.69.232-235. Epub 2015 Aug 4.
8
Fluid overload in hemodialysis patients: a cross-sectional study to determine its association with cardiac biomarkers and nutritional status.血液透析患者的液体超负荷:一项横断面研究,旨在确定其与心脏生物标志物和营养状况的关系。
BMC Nephrol. 2013 Dec 2;14:266. doi: 10.1186/1471-2369-14-266.
9
Thrombin-anti-thrombin levels and patency of arterio-venous fistula in patients undergoing haemodialysis compared to healthy volunteers: a prospective analysis.在接受血液透析的患者与健康志愿者中比较凝血酶-抗凝血酶水平与动静脉瘘通畅率:一项前瞻性分析。
PLoS One. 2013 Jul 2;8(7):e67799. doi: 10.1371/journal.pone.0067799. Print 2013.
10
Thrombophilia and arteriovenous fistula survival in ESRD.血栓形成倾向与终末期肾病患者动静脉瘘的生存
Clin J Am Soc Nephrol. 2013 Jun;8(6):962-8. doi: 10.2215/CJN.03860412. Epub 2013 Feb 14.